Clinical trials have primarily focused on testing myostatin inhibitors as potential treatments for various neuromuscular disorders, including Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy, inclusion body myositis, limb-girdle muscular dystrophies, as well as conditions like sarcopenia and cachexia [16]. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.